initial public offerings (IPOs) trading on American exchanges

Monday, January 5, 2015

FibroGen (FGEN) began trading on the NASDAQ on 14 November 2014


FibroGen, Inc. (FibroGen) is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat unmet medical needs. The Company focuses in the areas of fibrosis and hypoxia-inducible factor (HIF) biology. FibroGen’s products include Roxadustat (FG-4592), which is an oral small molecule inhibitor of HIF prolyl hydroxylases (HIF-PHs) in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and FG-3019, which is a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer and liver fibrosis. The Company’s subsidiaries include FibroGen Europe Oy (FibroGen Europe) and FibroGen China Anemia Holdings, Ltd. (FibroGen China).


409 Illinois St
SAN FRANCISCO, CA 94158-2509
United States

Key stats and ratios

Q3 (Sep '14)2013
Net profit margin-289.38%-14.63%
Operating margin-271.52%-7.78%
EBITD margin--2.80%
Return on average assets-44.23%-5.31%
Return on average equity--

No comments:

Post a Comment